Fast Forwarding Checkpoint Medicine
Striving to improve the quality of life by introducing the latest in medical technology for treating cancer and autoimmunity

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

Product Pipeline

Regen BioPharma is a biotechnology  company focused on stem cell and immunotherapies for specialty niche treatments.
​
Currently we are focused on aplastic anemia, gene silencing and small molecule development.
Complete listing, click "READ MORE".




​
​

Investors

December 15, 2015 SOURCE: REGEN BIOPHARMA INC.  Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate. Company to initiate Phase I Clinical Trial for IMmune Modulatory Personalized Cell Therapy in Treatment of Aplastic Anemia.
READ MORE>>>

​Investor resources
Regen BioPharma Inc. trades under the symbol RGBP on the OTC Bulletin Board and OTC PINK markets. Regen is a biotechnology company focused on...
​

Company News

News and press releases listed by year for reading and downloading.








​
​